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344Objectives:We reviewed the use of pediatric mechanical circulatory support before and after transplantation to
examinine current results and future strategies.
Methods: All patients listed for transplantation from January 2000 to December 2010 who required either ex-
tracorporeal membrane oxygenation (ECMO) or ventricular assist device (VAD) support before (‘‘intention to
transplant’’) or after transplantation were included. Indications for mechanical assistance, age, weight, duration
of support, complications while on support, causes of death, and overall actuarial survival were recorded.
Results: Thirty-seven patients were received VADs; 32 (86.5%) survived to transplantation. Postoperative hem-
orrhagic or thrombotic complications affected all of those under 15 kg. One patient in the survivor cohort dem-
onstrated focal neurologic findings. Three (8.1%) had panel reactive antibody levels of 10% or more while on
device support; all received transplants. ECMO as an intention to bridge to transplantation was used in 28 pa-
tients; 7 died, 7 were weaned, and 14 were bridged to transplantation. Nineteen patients required ECMO after
transplantation; 3 additional patients had percutaneous VAD support for late rejection. There was a significant
(P ¼ .02) difference in survival after listing for transplantation among those supported with ECMO, with VAD,
and those not supported with a device. No difference in posttransplant survival was demonstrated between those
patients supported with either ECMO or VAD before transplant compared with all others not bridged to trans-
plantation.
Conclusions: Both VAD and ECMO support are highly effective means of bridging patients to transplantation
and supporting patients after transplanatation. Ideally, the availability of smaller devices for children will have
a favorable impact on the morbidity related to anticoagulation in the smallest patients. (J Thorac Cardiovasc
Surg 2012;143:344-51)Over the past 2 decades, the use of ventricular assist devices
(VADs) as bridges to transplantation in adults has become
the standard of care worldwide. However, VAD use in chil-
dren in particular the specific choice of device and
method of support continues to be controversial. Until re-
cently, extracorporeal membrane oxygenation (ECMO)
represented the mainstay of mechanical ventricular assis-
tance in pediatric patients, particularly for those considered
‘‘too small for VAD.’’ The emergence of new, smaller de-
vices more appropriate for children has made available
a wider variety of candidate devices, albeit still with consid-
erable hemorrhagic and thromboembolic morbidity for
those less than 10 kg.1-5 For pediatric patients being
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The Journal of Thoracic and Cardiovascular Surginfluenced by patient size, the estimated duration of
support, and the relative feasibility for home discharge. In
contrast, after transplant, the increased risk of significant
infection and the potential morbidity associated with
reoperative sternotomy may influence device choice
considerably. We sought to review our single-center experi-
ence over a decade with the use of a variety of VAD types
and ECMO in children both as an intended bridge to trans-
plant and for temporary support in the setting of salvage
therapy for transplant rejection, with the aim of examining
current results and future strategies.METHODS
All patients listed for transplantation at the Morgan Stanley Children’s
Hospital of NewYork Presbyterian from January 1, 2000, to December 31,
2010, were reviewed, and those undergoing either ECMO or any form of
VAD support before (‘‘intention to transplant’’) or after transplantation
were included for analysis. Some of those who received posttransplant sup
port during this 10 year window initially underwent transplantation before
2000. In addition, 6 children who underwent placement of VADs at other
institutions but who were later managed and underwent transplantation at
our hospital were also included in the analysis.
Indications for mechanical assistance, age, weight, duration of device
support, complications while on device support (device exchange, reopera
tion, embolic or hemorrhagic complications, neurologic complications),
panel reactive antibody levels, and indicators of end organ function (creat
inine, aspartate transaminase [AST], alanine transaminase [ALT]), the needery c February 2012
Abbreviations and Acronyms
ALT ¼ alanine transaminase
AST ¼ aspartate transaminase
BTT ¼ bridge to transplantation (cohort)
ECMO ¼ extracorporeal membrane oxygenation
LVAD ¼ left ventricular assist device
POD ¼ postoperative day
PTT ¼ partial thromboplastin time
PVAD ¼ paracorporeal ventricular assist device
RVAD ¼ right ventricular assist device
VAD ¼ ventricular assist device
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transitioned to a different form of support, transplant, retransplant, death),
causes of death, and overall actuarial survival were recorded. Post VAD
end organ function data were obtained 1 week postoperatively where pos
sible, and for those supported for less than 1week, at 72 hours after implant;
1 patient on support for only 24 hours and all 6 patientswho underwentVAD
implantation at another hospital center were excluded from end organ func
tion data analysis. Panel ‘‘reactivity’’was classified as positive if either class
I or II panel reactive antibody was 10% or more by complement mediated
cytotoxicity assay in the presence of dithiothreitol.
Patients experiencing hemodynamic compromise within the first 30
days after transplantation were considered to exhibit primary graft failure
(rather than acute rejection). ‘‘Late’’ rejection was defined as occurring
more than 1 year postoperatively.
Management of Anticoagulation
Perioperative anticoagulation was managed by a multidisciplinary team
and for those patients more than 15 kg involved the commencement of un
fractionated heparin within the first 24 to 48 hours of the operating room,
once the chest tube output had decreased below 1 to 2 mL$kg 1$h 1, ulti
mately targeting a partial thromboplastin time (PTT) of 60 to 80 seconds.
Of this cohort, those patients managed with the Thoratec paracorporeal
VAD (PVAD; Thoratec Corporation, Pleasanton, Calif), HeartMate II
(Thermo Cardiosystems, Inc, Woburn, Mass), and Toyobo (Nipro Corpora
tion, Osaka, Japan) were subsequently transitioned to oral warfarin therapy
with a goal international normalized ratio of 2.5 to 3.0 seconds. Patients
with the Levitronix CentriMag (Thoratec Corporation, Pleasanton, Calif),
Abiomed BVS 5000 (Abiomed, Danvers, Mass), and Berlin Heart EXCOR
(Berlin Heart GmbH, Berlin, Germany) remained on heparin alone. For
those patients weighing less than 15 kg, our protocol evolved to ultimately
beginning unfractionated heparin in the operating room before transport,
with a goal PTTof 80 to 100 seconds. Additional aspirin and dipyridamole
were begun once patients were tolerating oral therapy. Patients on the
HeartMate XVE VAD received no heparin therapy and only aspirin.
Those exhibiting prothrombotic tendencies and those with difficulty
achieving goal anticoagulation were managed under the direction of a pedi
atric hematologist. Neither activated clotting time nor thromboelastogra
phy was used postoperative to guide anticoagulation protocols.Percutaneous Support
In the cardiac catheterization laboratory, an 8 mm Dacron graft was
sewn end to side to the axillary artery and an Abiomed Impella LP was in
serted under fluoroscopic guidance. A Swan Ganz catheter (Edwards Life
Sciences, Irvine, Calif) was placed via the internal jugular veins and
subsequently replaced with a stiff guidewire (Meier guidewire, Boston Sci
entific, Natick, Mass), and a BioMedicus (Medtronic, Inc, Minneapolis,The Journal of Thoracic and CaMinn) femoral venous cannula was introduced leaving its tip in the main
pulmonary artery. A second femoral venous cannula was placed via the
common femoral vein and adjusted with its tip in the right atrium for right
VAD (RVAD) inflow. These latter 2 cannulas were connected to a Centri
Mag circuit (Thoratec) and both left and right sided devices actuated.
Technical Modifications
Early in the experience, all VAD cases were performed on cardiopulmo
nary bypass, and every attempt was made to close intracardiac communica
tions to prevent postoperative right to left shunting.This strategy evolved to
performing someVAD implants off bypasswhen possible, and even in those
pediatric patients with significant intracardiac communications (including
multiple ventricular septal defects) there was no significant difficulty ‘‘bal
ancing’’ shunting, nor were there increased neurologic sequelae.
Additionally, in the early experience, the patients supported by the Cen
triMag device who experienced thrombotic complications were supported
by the ‘‘adult’’ CentriMag circuit (3/8 inch tubing and hard connectors)
although some of these complications were ameliorated by using 3/8 to
1/4 inch X coated taper tubing (Terumo Cardiovascular, Ann Arbor,
Mich). For children 10 kg and under, we currently use the PediMag device
(Thoratec), which requires higher revolutions per minute to achieve com
parable flow, ¼ inch tubing, and connectors.
The ECMO circuit used from January 2000 through October 2007 con
sisted of a Jostra HL 20 (Maquet, Inc, Wayne, NJ) roller pump with ½ inch
or 3/8 inch raceway tubing, a Medtronic silicone 2500 or 3500 oxygenator
(Medtronic, Inc), an arteriovenous bridge, and several pigtails and dia
monds. The total prime of this circuit was approximately 1000 mL. Since
October 2007, the ECMO circuit has consisted of 3/8 inch tubing, a Rota
flow (Maquet, Inc) centrifugal head, aQuadroxD (Maquet, Inc) oxygenator,
and no arteriovenous bridge, pigtails, or diamonds. The total prime of the
contemporary circuit is 360mL. In addition, 1 patient underwent ECMOaf
ter transplantation for primary graft failure using a PediMag pump, a Quad
rox Pediatric iD oxygenator, and ¼ inch tubing and connectors throughout.
Statistical Analysis
All continuous variables are expressed as mean  standard deviation.
Preoperative and postoperative laboratory values were compared by using
a paired Student t test. Comparisons between groups were made using
a 2 sample Student t test. For survival from listing and transplant,
Kaplan Meier survival analysis was used and cumulative survival graphs
created. Comparisons of survival between groups were made using the
log rank test. All statistical tests were 2 sided. Statistical analyses were
performed using SPSS Statistics 18 for Windows (IBM Corp, Somers,
NY). Patients undergoing ECMO bridge to VAD support were included
in the ‘‘VAD’’ cohort for actuarial survival analysis.
This study was approved by the Institutional Review Board of Columbia
University.
RESULTS
VAD Patient Cohort
Between January 1, 2000, and December 31, 2010, 37 pa-
tients were implanted with VADs as intended bridge to
transplantation (BTT cohort). During that time interval,
269 overall pediatric patients were listed for transplantation
and 206 patients received a transplant. Over the decade of
study, a variety of devices were used (Table 1). Causes of
heart failure in the BTT cohort included dilated cardiomy-
opathy in 28 (75.7%), myocarditis in 4 (10.8%), postche-
motherapy cardiomyopathy in 2 (5.4%), restrictive
cardiomoypathy in 1 (2.7%), peripartum cardiomyopathy
in 1 (2.7%), and postcardiotomy shock in 1 (2.7%). Onerdiovascular Surgery c Volume 143, Number 2 345
TABLE 1. Demographics of the VAD study cohort
Device n Age (y) Weight Duration (d) Outcome
BVS 5000i 2 12.9  2.6 53  1.4 3.0  2.8 1 Transplant/1 weaned
CentriMag BiVAD 10 7.6  5.0 30.2  22.3 12.1  8.4 6 Transplant/4 died
PediMag BiVAD 1 0.75 5.8 17 1 Transplant
EXCOR BiVAD 1 0.3 3.8 6 Died
HeartMate (7XVE/2HMII) 9 15.0  4.0 66.5  51.8 75.7  19.9 9 Transplant
PVAD BiVAD 8 14  2.2 58.5  15.7 43.6  40.3 8 Transplant
Toyobo (1 BiVAD/5 LVAD) 6 13.3  4.8 33.7  11.0 313.8  283.6 6 Transplant
CentriMag/Impella 3 14.3  3.1 56.8  10.1 5.0  2.0 3 Weaned
BVS 5000i, Abiomed, Danvers, Mass; CentriMag and PediMag, Thoratec Corporation, Pleasanton, Calif; EXCOR, Berlin Heart GmbH, Berlin, Germany; HeartMate, Thermo
Cardiosystems, Inc, Woburn, Mass; Toyobo, Nipro Corporation, Osaka, Japan. VAD, ventricular assist device; BiVAD, biventricular assist device; PVAD, paracorporeal
ventricular assist device; LVAD, left ventricular assist device.
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transitioned to an Abiomed (Abiomed, Inc) BVS500i after
a Ross procedure. He was successfully weaned from Bi-
VAD support only to require transplant 11 months later. An-
other 2 patients were transitioned from ECMO to Thoratec
PVAD (Thoratec Corporation). Six patients had undergone
insertion of a Toyobo (Nipro Corporation) VAD at another
institution but received their transplant at our institution. Of
these 37 patients in the BTT VAD cohort, 32 (86.5%)
survived to ultimate transplantation.
In the BTT cohort, 5 patients (13.5%) died on device
support. One patient with a Berlin Heart EXCOR BiVAD
required pump exchange and later died of thromboembolic
stroke on postoperative day (POD) 6. The remaining 4 un-
derwent Thoratec CentriMag biventricular support; 1 died
of progressive thrombotic complications (POD 13), 1 of
thromboembolic stroke (POD 27), and 2 of sepsis and mul-
tisystem organ failure (POD 14, POD 24). Of note, 3 of
these CentriMag patients weighed less than 15 kg.
Postoperative hemorrhage requiring mediastinal explora-
tion affected 7 (70%) of those in the CentriMag cohort,
4 (50%) of those in the Thoratec PVAD cohort, and the 1
patient with Levitronix (Levitronix, Waltham, Mass) Pedi-
Mag BiVAD support. None of those with the Abiomed
BVS and 1 patient (of 9) with a Thoratec HeartMate
(XVE or HeartMate II) device had bleeding complications
mandating reoperation.
Postoperative thrombotic events requiring device ex-
change occurred in 3 patients. The EXCOR patient (3.8 kg)
required device exchange on POD 4 for thrombus below the
RVAD inflow valve; thrombus later developed in both the
left and right pumps. The CentriMag patient (10.8 kg) re-
quired exchange on POD 1 for clot within the left ventricular
assist device (LVAD) inflow tubing; he later received a trans-
plant. One Toyobo patient (17.0 kg) had a subdural hemor-
rhage develop in the setting of an elevated international
normalized ratio requiring cessation of anticoagulation
and neurosurgical intervention. During this period without
anticoagulation, a thrombus developed in the device, mandat-
ing exchange for a CentriMag system (with later systemic
heparinization),which successfullybridgedhim to transplant.346 The Journal of Thoracic and Cardiovascular SurgWhen analyzed on the basis of patient size, all of those
patients less than 15 kg had either a hemorrhagic or throm-
botic complication after VAD implantation.
End-organ dysfunction, as measured byAST/ALTand se-
rum creatinine before and after VAD implantation, demon-
strated a trend toward improvement across all parameters:
AST (192.6  319.7 U/L before, 90.23  79.6 U/L after),
ALT (156.5 323.6 U/L before, 72.3 64.1U/L after), cre-
atinine (1.1  0.7 mg/dL before, 0.9  0.8 mg/dL after).
Perioperative continuous venovenous hemofiltrationwas re-
quired in 7 patients (2 of whom died of mutiorgan failure),
no patients required hemodialysis, and no patients were per-
manently dialysis dependent after transplant. One patient
(PVAD) in the survivor cohort experienced an acute focal
neurologic event while on device support. Although unclear
whether his subdural hemorrhage and basal ganglia infarcts
represented oldwatershed events (with conversion in the set-
ting of anticoagulation) or new device-related complica-
tions, their clinical manifestation (visual field deficits)
have since largely resolved. One patient (Toyobo) had a sub-
dural hemorrhage with headache (described above), and 1
patient (CentriMag) had a critical care neuropathy that re-
solved. Only 3 (8.1%) patients in the VAD cohort had panel
reactive antibody levels of 10% or greater while on device
support. Of these, 1 received intravenous immunoglobulin
therapy with plasmapheresis, 1 received intravenous immu-
noglobulin therapy with mycophenolic mycophenolate mo-
fetil, and 1 received no therapy. All 3 underwent successful
transplantation with pre cardiopulmonary bypass exchange
transfusions and at last follow-up did not demonstrate panel
reactivity.
In addition to theBTT cohort, 3 patients underwent percu-
taneous VAD support for hemodynamically significant late
rejection (age, 14.3 3.1 years; weight, 56.8 10.1 kg; du-
ration of support, 5 2 days), and all 3 survived to explant.
ECMO Patient Cohort
During the study period, 28 patientswere placed onECMO
who were listed for transplantation. Of these, 7 (25%)
patients died while on support (2 dilated cardiomyopathy,
1 meningitis/shock, 1 myocarditis, and 3 postcardiotomy).ery c February 2012
FIGURE 1. Survival after listing. ECMO, Extracorporeal membrane
oxygenation; VAD, ventricular assist device.
FIGURE 2. Survival after transplant. MCS, Mechanical circulatory
support.
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the need for later transplantation, all but 1 of whom hadmyo-
carditis (1 newborn infant had cardiogenic shock in the setting
of a cryptogenic myocardial infarction). The remaining 14
(50%) patients were bridged to transplantation. When ana-
lyzed with regard to era of ECMO (pre/post October 2007),
survival of this ECMO ‘‘BTT’’ cohort before October 2007
was 68.4%, and after October 2007 was 88.9%.
A total of 19 patients underwent ECMO after transplan-
tation. Of these patients, 10 underwent ECMO support for
acute rejection, of whom 3 (30%) died, 6 (60%) were
weaned, and 1 (10%) required retransplantation. ECMO
support for primary graft failure in the first 2 weeks after
transplant was required in 8 patients, of whom 4 (50%)
died, 3 (37.5%) were weaned, and 1 (12.5%) required re-
transplantation. Both cohorts were comparable in duration
of support (7.3  5.0 days vs 6.8  2.1 days), although
the acute rejection cohort was older (10.1  7.6 years vs
2.6 3.2 years) and larger (30.7 17.0 kg vs 9.6 5.1 kg).Kaplan-Meier Actuarial Survival
Kaplan-Meier survival analysis demonstrated a signifi-
cant (P ¼ .02) difference in actuarial survival after listing
for transplantation among those supported with ECMO
with VAD and those not supported with a mechanical device
(Figure 1) (ECMO vs no support, P¼ .001; ECMO vs VAD,
P ¼ .006; VAD vs no support, P ¼.515). In contrast, no
difference in posttransplant survival was demonstrated be-
tween those patients supported with either ECMO or VAD
before transplant compared with all others not bridged to
transplantation (P ¼ .84 (Figure 2).DISCUSSION
On the basis of ongoing success in the adult population
with VAD therapy as temporary or permanent ventricularThe Journal of Thoracic and Casupport, growing enthusiasm has evolved over the past 20
years to extend the benefit of mechanical ventricular assis-
tance to pediatric patients before and after transplanta-
tion.1-6 Although initial forays involved simple application
of adult-sized devices to older adolescents and teenagers,
subsequent adaptation of these devices and the development
of new, smaller devices of a size appropriate for small chil-
dren have offered promising alternatives for increasing num-
bers of pediatric patients.7 However, considerablemorbidity
still exists with the application of any such devices for in-
fants and small children, in particular related to the difficulty
of accurately anticoagulating these patients, and thus the
attendant risks of thrombosis, embolism, or significant
hemorrhage.
For all transplant recipients, a risk of primary graft failure
or rejection with cardiovascular collapse always exists. In
selected instances, the need for support may be purely he-
modynamic (and not pulmonary), and strategies to avoid
the use of an oxygenator in line (ie, VAD not ECMO)
may thus be favored. At our center, the recent availability
of percutaneous VADs for temporary support has provided
logical candidate devices for use in this posttransplant
setting.
We sought to review our 10-year experience with the use
of different kinds of mechanical ventricular assistance be-
fore and after transplantation. In limiting this cohort to
those listed for transplantation, we intended to refine a strat-
egy specific to this group and not include those in whom
ventricular recovery is likely; for example ‘‘simple’’ post-
cardiotomy failure where the considerations of device
choice based on longer durations of support are less rele-
vant. Our findings are notable for 5 salient findings.
First, VAD therapy can be a highly successful means of
supporting pediatric patients across a wide range of sizes.
We have tended, in general, to favor biventricular support
for patients in whom there is any contention regarding therdiovascular Surgery c Volume 143, Number 2 347
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larger patients in whom a long waiting time is projected,
where possible we endorse a long-term device with the pos-
sibility of home discharge (eg, HeartMate XVE/HeartMate
II, PVAD).
Second, bleeding and/or thrombosis remain a major
source of morbidity and mortality for patients less than 15
kg in weight. This particular problem has been highlighted
previously by investigators at Great Ormond Street, who
implicated, amongother reasons, the immaturity of the coag-
ulation cascade in small children.2,7 Our management of
these smaller patients has evolved considerably over
the past decade and now involves several key features:
(1) Where possible (unless the possibility of ventricular
recovery is high), we use atrial inflow performed with low-
dose heparinization off bypass. This has markedly reduced
our initial rate of hemorrhage and re-exploration. (2) We
use heparin-coated (Carmeda; Medtronic, Inc, Minneapoils,
Minn) cannulas and connectors and biocompatible (Smart;
Cobe Cardiovascular, Arvada, Colo) tubing. (3) We begin
unfractionated heparinization in the operating room before
transfer, which is dosed for a goal PTTof 100 to 120 seconds
within the first several hours postoperatively. Once extu-
bated, patients are also begun on aspirin and/or warfarin
and a second antiplatelet agent once tolerating oral medica-
tion. We have not used activated clotting time or thromboe-
lastography to guide our postoperative care owing to
specific institutional restrictions.
Using our current strategies of the PediMag device with
a smaller (¼-inch) circuit, we have seen significantly less
thrombus (and bleeding events) with the PediMag device
in both the bridge-to-transplant setting and for several other
nontransplant patients in whom we have used it for postcar-
diotomy shock (data not shown).8,9 While still preliminary,
our PediMag experience has been promising with regard to
ease of implantation, overall cost, and morbidity; issues of
durability and applicability will require further analysis. In
the past we have been less inclined to use bridge-to-
transplant VAD support for multiple reoperative congenital
candidates (favoring ECMO). However, using this new ap-
proach, and on the basis of recent experience in the litera-
ture, we may be more liberal in using this therapy.10
Of interest, none of our patients in whom theHeartMate II
device was implanted had the development of acquired von
Willebrand deficiency, as has been demonstrated exten-
sively in the adult experience.11Although thiswas fortunate,
the possibility of its occurrence remains a consideration for
those patients anticipating a long waiting time. As experi-
ence grows with the use of this device in children, the mag-
nitude of the acquired von Willebrand phenomenon will
become more well defined.12 Also of note is our low
incidence of acute neurologic morbidities in the entire
VADsurvivor cohort.However, 3 patients in the nonsurvivor
group died of profound neurologic events.348 The Journal of Thoracic and Cardiovascular SurgThird, for those bigger patients with refractory late rejec-
tion, we have found the percutaneous therapy of Impella
LVAD with CentriMag RVAD to be efficacious and cost ef-
fective. This approach obviates the morbidity of a reopera-
tive sternotomy, with its attendant risks of both bleeding and
infection, the latter being a considerable concern in these
patients for whom treatment requires substantial pharmaco-
logic impairment of immune function. This combination
VAD is quick to deploy and easy to wean (the sidearm graft
can be stapled and the incision closed in the interventional
suite). For those smaller patients in this candidate cohort,
such a strategy may also avoid significant limb ischemia.
We used the Impella 2.5 in this setting given its rapid avail-
ability. However, for larger patients this clearly only repre-
sents partial support; therefore, the current availability of
Impella 5.0 would argue for its use where feasible. Al-
though we supported patients for as long as 1 week with
this strategy, should their function have remained poor, con-
sideration of transition to a longer-term VAD would have
been necessary. In as much as this approach affords the flex-
ibility to insert an oxygenator into the RVAD limb when
necessary, we have favored VAD support over ECMO
where possible, a strategy that is substantiated by recent re-
ports of the 50% success rate of ECMO in this setting.13
Our results with posttransplant ECMO support for primary
graft failure or rejection mirror those in the literature, likely
reflecting the dire clinical scenario warranting its practice.
Unlike the Denver group, we have had several survivors sup-
ported for more than 4 days (1 as long as 19 days) while ag-
gressive antirejection therapy was administered.14,15 We are
judicious in the consideration of retransplantation for
primary graft failure, especially in the setting of acute
rejection, recognizing that outcomes in this setting may be
limited.
Fourth, only 8% of our VAD cohort had significant anti-
HLA panel reactive antibody levels while on device sup-
port, despite the fact that many received multiple blood
transfusions. This is in contrast with other recent reports
suggesting rates of sensitization as high as 35%.15 We as-
siduously re-evaluate these levels while on VAD support
and currently treat those sensitized patients with the
combination of intraoperative exchange transfusion, post-
operative plasmapheresis when there is a positive cross
match, and maintenance steroids for at least 6 months after
transplantation.
Fifth, as has been demonstrated in several multi-
institutional database analyses, our cohort showed no signif-
icant survival disadvantage after transplant for those patients
who survive to transplantation bridged with either ECMO or
VAD (Figure 2).16,17 The differences in actuarial survival
from the time of listing for transplantation among the
cohorts (Figure 1) likely stems from several early deaths in
our ECMO group before circuit design change in 2007.
Although anecdotal, we believe that the smaller circuitery c February 2012
FIGURE 3. Our general approach to mechanical ventricular assistance.
ECMO, Extracorporeal oxygenation; BTT, bridge to transplantation;
VAD, ventricular assist device; P VAD, paracorporeal ventricular assist de
vice; I VAD, implantable ventricular assist device; BSA, body surface area.
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has reduced some of the morbidity experienced with the
earlier circuit.
In summary, we have found it helpful to have a variety of
mechanical ventricular assistance available so as to tailor
the device strategy to the patient. Although we have no
firm algorithm in this setting, our general approach is out-
lined in Figure 3. Our initial indication for ECMO use per-
tains to the need for oxygenation, and we favor VAD
support where feasible, given (1) the substantial advantages
of potential extubation and ambulation/rehabilitation and
(2) the disadvantages of having an oxygenator in line (eg,
activation of inflammation, increased requirement for anti-
coagulation, and limited durability). This inclination is in
keeping with other reports demonstrating superior survival
in patients supported with VAD rather than ECMO.18,19 The
selection of VAD devices is directed mostly by size and the
need for univentricular or biventricular support; however,
the optimal strategy to support patients in the ‘‘gray
zone’’ of size (15-35 kg) remains somewhat patient-
specific. For those patients in whom neurologic status is
in question, we have used a ‘‘bridge to decision’’ approach,
initially using a temporary device or ECMO until a more de-
finitive neurologic prognosis can be determined, at which
point transition to a longer-term device can take place. Al-
though we have favored using ECMO to support patients
with complex congenital heart disease in the past, we would
imagine them to be VAD candidates (following this algo-
rithm by size) in many circumstances.
Mechanical circulatory support using a variety of devices
is a highly effective means of both bridging patients to
transplantation and supporting patients after transplantation
during hemodynamic crises. The more widespread avail-
ability of smaller and potentially implantable devices for
children will only serve to improve these strategies, while
potentially affecting favorably the substantial morbidity
related to anticoagulation in the smallest patients.The Journal of Thoracic and CaReferences
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Dr J. William Gaynor (Philadelphia, Pa). I congratulate
Dr Chen and his co investigators on a very interesting presentation
and thank them for allowing me to review the manuscript.rdiovascular Surgery c Volume 143, Number 2 349
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DThis is an important subject. As we have all seen, increasing
numbers of children are listed for cardiac transplantation. In light
of the nonincreasing donor pool, waiting times continue to in
crease and the potential loss of patients on the waiting list is a sig
nificant problem. The findings of this study are very similar to our
findings in a similar sized patient cohort, that overall survival to
transplant is excellent and that survival after transplant from
a VAD is equivalent to that of patients undergoing transplantation
without a VAD. I think this is a very effective technique.
We also see the same problems with thrombosis and hemor
rhage, particularly in the very small devices and in the very small
EXCOR devices, so our overall outcomes are very similar. We do
have some management differences, and that is going to be the
focus of my question.
We rarely need to use BiVAD support. We have a very similar
patient mix and primarily cardiomyopathies, and in 33 patients
we have only needed to use BiVAD support twice. We place an
LVAD in the operating room, attempt to wean from bypass, usually
with inhaled nitric oxide, and if we do not require excessive inotro
pic support, we have been very successful and continue with that.
What are your criteria for a BiVAD? How do you decide? Are
you continuing to use a lot of BiVAD support?
Dr Chen. Thank you. Excellent question. Our management is
very similar to yours insofar as we would always like to try to
get away with one pump only, if only because more pumps just
mean more potential for complications.
Earlier in our series we were seeing more children who were re
ally in shock and going to the operating room while undergoing
chest compressions. Those children are the least likely to come
away with a single sided device only. As we have gotten more
comfortable and more aggressive, the likelihood of catching pa
tients earlier who will have reasonable right ventricular function
is good.
I also think that in the later part of this experiencewewere using
many fewer pulsatile, fill to empty left ventricular inflow devices.
None of these, the centrifugal or axial flow devices, decompresses
the ventricle quite as much and probably causes as much septal
shift. So more recently I am hoping, as you point out, that we
will be using fewer and fewer BiVADS and more and more LVADs
as long we can effectively manage some right heart failure
medically.
DrGaynor.You also mentioned that you switched to atrial can
nulation. We have continued to use primarily apical cannulation
except in patients with restricted physiology, and we believe that
we get better decompression of the ventricle. We have not seenma
jor problems with the septal shifting. When would you use atrial
cannulation now, if ever?
Dr Chen. That is a relatively new finding for us. It has been
prompted a little bit by the hemorrhage/thrombosis component,
which is that putting in the 2 atrial cannulas is very easy off
pump. With this strategy, you can get away with half dose heparin
and the bleeding is trivial in the operating room.
The disadvantage, of course, is that the decompression of the
ventricle is less effective.Also, there is a possibility that if the aortic
valve does not open, these children will have stasis in the left ven
tricle and later clot if we do not start fairly aggressive anticoagula
tion quickly enough. Some of the devices, of course, cannot be
inserted atrially, but it is a much simpler approach if it is possible.350 The Journal of Thoracic and Cardiovascular SurgDr Gaynor. I have 1 final question from the manuscript, which
you did not address in the presentation, concerning the manage
ment of patients who have intracardiac shunts. We always do
a very careful search for intracardiac shunts, and we have enclosed
them if we know we have them. We had 1 patient with an undiag
nosed patent foramen ovale who was significantly desaturated
when he came off LVAD support. Youmentioned in themanuscript
that with this off pump technique you will leave patients with
intracardiac shunts and have not seen that problem. Could you
expand on that?
Dr Chen. It was really more out of good luck, I think, than any
thing. Regarding the intracardiac shunt component, a lot of these
newer continuous flow devices do not decompress the ventricle
enough that we get as much right to left shunting as we used to
with their fill to empty predecessors. I was very concerned in 1 pa
tient, the smallest patient here, who had a BiVAD and multiple
ventricular septal defects, that it was going to be hard to control
the degree of shunting. However, it ended up not being so much
of a problem. Atrial cannulation can be tricky with regard to atrial
communications, though, and I suspect those probably still need to
be closed.
Dr Gaynor. This answer brings up a further question. Most of
our cases are bridged to transplant; we almost never bridge to re
covery. We are always concerned that children frequently come in
with high left atrial pressures and pulmonary edema, and we are
concerned about dropping that left atrial pressure to improve the
lungs. If you are using a device that does not decompress, will
the atrial cannulation alone drop the left atrial pressure sufficiently
to allow the lungs to recover?
Dr Chen. I do not know the answer to that. I would assume that
the atrial cannulation probably will. I certainly do not think ECMO
does though. It has definitely been our policy that if you are bridg
ing to transplant with ECMO and you suspect high atrial pressures,
you have to go to the catheterization laboratory for a septostomy at
the time of instituting ECMO support, or very soon thereafter.
Dr Carl L. Backer (Chicago, Ill). For the patients whom you
are supporting with ECMO, what is your decision tree for where
to do the cannulation neck, femoral, or median sternotomy?
We recently had an older child who came in with myocarditis.
I put her on ECMO through the chest and she came off ECMO
and went home after she was treated. The advantage of this in
the older child is that there are no femoral or neck vessel compli
cations. When these patients come in, it seems that there is always
some discussion about where to do the ECMO cannulation. What
is your strategy?
Dr Chen. For the smaller children and our cutoff ends up be
ing about 2 years we go on through the neck. The hard group is
that between about 5 kg and about 15 kg, because we have had
a fair number of groin complications with that size range, even
with the T’d off sidearm that goes through the dorsalis pedis.
When the patients get to be older and bigger, you can easily go
with 2 venous cannulas, neck and groin, and femoral artery. It is
just that middle group, I think, that is probably the right group to
be having a sternotomy because it is much simpler and the vascular
complications are substantial.
Dr Hajime Ichikawa (Osaka, Japan). I am really interested in
your atrial cannula. We used to use an atrial cannula with Japanese
Toyobo LVADs and we had a lot of problem with thrombosis.ery c February 2012
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DDo you change the anticoagulant regimen when using an atrial
cannula?
Dr Chen.May I ask a question? Is the thrombosis in the pump
or in the ventricle?
Dr Ichikawa. In the ventricle.
Dr Chen.We have worried a lot about thrombosis in the ventri-
cle. We definitely run PTTs pretty high on all of these children; es-
pecially in the smaller children, we will run the PTTs well above
100. This is not necessarily based on the flow in the ventricle
and so forth, but just as a general policy.
Dr Shunji Sano (Okayama, Japan).When I look at your table,
the average duration is relatively short compared with the Toyobo
device. The Toyobo device is completely different, almost 1 year.
But most of these patients are relatively large children. So
even with a Toyobo device, you use the adult size device. Why
is the duration long and why was there only 1 episode of
thromboembolism?
When I look at the small child, in this case comprising only 3
patients—1 with a Berlin Heart, 1 with the PediMag, and 1 with
the Abiomed—they weighed less than 10 kg. The longest duration
was 17 days. How long do you think it is safe to wait for transplantThe Journal of Thoracic and Ca
Hwith these 3 devices in very small babies weighing less than 10
kg—1 month or 6 months or 1 year?
Dr Chen. The answer as to why that waiting time was so long
for the Toyobo patients is that, as you know, children in Japan have
to wait a fair amount of time for a potential donor. Each US pro-
gram can only have 5% of their transplant volume as comprised
of foreign national candidates, so sometimes these international
children have to wait for the calendar year to turn over before
we can accept them. There can be quite a bit of time for waiting
and it takes time to raise money and so forth.
Early in our experience we used the adult CentriMag circuit
rather than the PediMag; that is a 3/8–inch connection all the
way around. It is actually a fairly large priming volume. A lot of
children who were just over 10 kg in this group, about 11 to 13
kg, would form a lot of early thrombus in the tubing, and so I started
adapting to exchanging the tubing routinely at 2 weeks. We carried
some of those patients up to about 6 weeks.
I do worry, though, when we put the smallest children on de-
vices. We really try to get the transplant done as quickly as possi-
ble. The good news is that most of them can receive transplants
across ABO blood groups because of their age.rdiovascular Surgery c Volume 143, Number 2 351
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